One avenue that merits exploration is the repurposing of reagents that were developed for use with SARS-CoV, as many are both extremely effective and commercially available.Ĭoronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses with exceptionally large genomes of up to 32 kb on a single RNA molecule. There is an urgent need for tools to study this novel coronavirus, as part of the effort to quickly and safely develop vaccines and treatments. SARS-CoV-2 falls within the family Coronaviridae, and can be further subcategorized as a Betacoronavirus of lineage B. SARS-CoV-2 has been designated as a strain of the same species as the original SARS coronavirus (SARS-CoV) due to a high degree of sequence similarity. At the time of writing, there are over seven million confirmed infections and four hundred thousand fatalities globally. The recent emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 has led to an ongoing global COVID-19 pandemic and public health crisis. Moreover, our study provides critical information about the propensity of SARS-CoV antibodies to cross-react with SARS-CoV-2 and highlights its relevance in defining the clinical significance of such antibodies to improve testing and guide the development of novel vaccines and therapeutics. These antibodies should help facilitate further research into SARS-CoV-2 basic biology. Remarkably, a high proportion of the antibodies we tested showed cross-reactivity, indicating a potentially generalizable theme of cross-reactivity between SARS-CoV and SARS-CoV-2 antibodies. We evaluated the utility of these antibodies against SARS-CoV-2 in a variety of assays, including immunofluorescence, ELISA, biolayer interferometry, western blots, and micro-neutralization. ![]() We assessed a total of 10 antibodies (six for Spike, two for Membrane, and one for Nucleocapsid and Envelope viral protein). Here, we extensively characterized antibodies of the SARS-CoV structural proteins for their cross-reactivity, experimental utility, and neutralization of SARS-CoV-2. Repurposing the existing tools, including antibodies of SARS-CoV, is an effective way to accelerate the development of therapeutics for COVID-19. There is currently a lack of biological tools to study the replication cycle and pathogenesis of SARS-CoV-2, the etiological agent of COVID-19.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |